Published: 2021-07-26

Efficacy and safety of different terbinafine regimens in patients of recurrent tinea corporis and cruris

Noopur Verma, Savita Verma, Surbhi Dayal, M. C. Gupta


Background: Tinea corporis and cruris is said to be recurrent when there is relapse of sign and symptoms after 6 weeks of cure. Recently, there has been increase in cases of recurrent tinea corporis and cruris, with atypical lesions. This study was done to establish efficacy and safety of different terbinafine regimens against recurrent tinea corporis and cruris.

Methods: Sixty patients with clinically and mycologically diagnosed recurrent tinea corporis and cruris were enrolled and divided into three groups. Group A was administered oral terbinafine 500 mg once daily for 2 weeks, group B was given terbinafine 250 mg once daily for double duration i.e., 4 weeks, and group C was given standard treatment which is 250 mg once daily for 2 weeks. Physician assessment four-point scale (PA4PS) and KOH wet mount were assessed for clinical and mycological efficacy. Biochemical laboratory parameters (liver function tests and kidney function tests) and adverse drug reactions were assessed for safety.

Results: At the end of 6 weeks, reduction in PA4PS from baseline was 46.5%, 95.8%, and 20.4% in groups with double dose, double duration and standard therapy respectively with statistically significant (p<0.05) improvement in group with double duration. Mycological cure at the end of 4 weeks was 80%, 100% and 50%. There was no safety concern in any of the groups.

Conclusions: Double duration of terbinafine was found to be more efficacious and safer.


Recurrent tinea corporis, Recurrent tinea cruris, Terbinafine, KOH mount, PA4PS

Full Text:



Rajagopalan M, Inamdar A, Mittal A, Miskeen AK, Srinivas CR, Sardana K et al. Expert consensus on the management of dermatophytosis in India (Ectoderm India). BMC Dermatol. 2008;18:6.

Sharma Y, Jain S, Chandra K, Khurana VK, Kudesia M. Clinico-mycological evaluation of dermatophytes and non-dermatophytes isolated from various clinical samples: A study from north India. J Res Med Sci. 2012;17:817-8.

Dogra S, Uprety S. The menace of chronic and recurrent dermatophytosis in India: Is the problem deeper than we perceive? Indian Dermatol Online J. 2016;7(2):73-6.

Babu PR, Pravin AJS, Deshmukh G, Dhoot D, Samant A, Kotak B. Efficacy and Safety of Terbinafine 500 mg once daily in patients with dermatophytosis. Indian J Dermatol. 2017;62:395-9.

Banerjee M, Ghosh AK, Basak S, Das KD, Gangopadhyay DN. Comparative evaluation of effectivity and safety of topical amorlfine and clotrimazole in the treatment of tinea corporis. Indian J Dermatol. 2011;56(6):657-62.

Kumar A, Budania N, Sharma P, Singh M. A comparative study of efficacy of terbinafine and fluconazole in patients of tinea corporis. Int J Biomed Res. 2013;04:11.

Bhatia A, Kanish B, Badyal DK, Kate P, Choudhary S. Efficacy of oral terbinafine versus itraconazole in treatment of dermatophytic infection of skin-A prospective, randomized comparative study. Indian J Pharmacol. 2019;51:116-9.

Sirohi S, Bhutani S, Cheema C, Kaur G, Singh SP. Comparison of safety and efficacy of oral terbinafine with amphotericin B gel and sertaconazole cream for the treatment of tinea corporis and its effect on quality of life of patients. Int J Dermatol Clin Res. 2017;3(1):18-21.